ARTICLE | Company News
EPO rejects Soliris patent, schedules oral hearing
May 8, 2018 8:39 PM UTC
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said the European Patent Office has rejected a patent that would extend exclusivity through 2027 for rare disease drug Soliris eculizumab. An oral hearing has been scheduled for Feb. 5, 2019.
The company told BioCentury that the patent process in Europe "involves several rounds" and that the issues raised by the European Patent Office are similar to those raised in the U.S. and Japan, where corresponding patents have already been issued. ...
BCIQ Company Profiles
BCIQ Target Profiles